ABT vs ACN Stock Comparison

Scores Breakdown

Metric	ABT	ACN
📈 Growth	22/30	22/30
💰 Profitability	17/20	18/20
🏦 Financial Health	15/20	18/20
💵 Valuation	12/20	16/20
⚠️ Risk (lower is better)	4/10	4/10
Overall Score	72/100	80/100

Side-by-Side Summaries

ABT Analysis	ACN Analysis
📈 Growth & Financial Trajectory Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects). 💰 Margins & Cash Flow Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest. 🛡️ Balance Sheet & Liquidity Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience. ⚠️ Key Drivers & Risks Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios. Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.	📈 Growth & Financial Trajectory Over 8 quarters, revenues moved from $16.41B (2024 Q4) to $18.72B (2026 Q3), a cumulative rise of about 14%. Net income increased from roughly $1.68B to $2.34B, up about 39%, signaling improving operating leverage as scale widens. The trend shows quarterly fluctuations but an overall positive trajectory with gradually rising profitability. 💰 Margins & Cash Flow Gross margin remains in the 32-34% range, supporting durable profitability. Operating margin hovers around 16-17%, indicating meaningful operating leverage with revenue growth. Net cash flow from operating activities stays robust, averaging near $3.7B per quarter; the latest quarter shows a positive, albeit modest, overall cash position as investing and financing outflows offset operating cash flow. 🛡️ Balance Sheet & Liquidity Current assets around $28-29B vs. current liabilities near $19-22B, implying a healthy liquidity cushion (latest current ratio ~1.3–1.4). Noncurrent liabilities about $13-14B against equity of roughly $31-33B, with total assets near $63-69B, indicating solid balance-sheet resilience and solvency dynamics. ⚠️ Key Drivers & Risks Drivers: AI & Data/Cloud transformation demand; scalable global services with cross-sell opportunities. Risks: cyclicality in IT spend, valuation sensitivity to growth expectations, competitive intensity.

ABT Analysis

ACN Analysis

📈 Growth & Financial Trajectory

Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects).

💰 Margins & Cash Flow

Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest.

🛡️ Balance Sheet & Liquidity

Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience.

⚠️ Key Drivers & Risks

Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios.
Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.

📈 Growth & Financial Trajectory

Over 8 quarters, revenues moved from $16.41B (2024 Q4) to $18.72B (2026 Q3), a cumulative rise of about 14%. Net income increased from roughly $1.68B to $2.34B, up about 39%, signaling improving operating leverage as scale widens. The trend shows quarterly fluctuations but an overall positive trajectory with gradually rising profitability.

💰 Margins & Cash Flow

Gross margin remains in the 32-34% range, supporting durable profitability.
Operating margin hovers around 16-17%, indicating meaningful operating leverage with revenue growth.
Net cash flow from operating activities stays robust, averaging near $3.7B per quarter; the latest quarter shows a positive, albeit modest, overall cash position as investing and financing outflows offset operating cash flow.

🛡️ Balance Sheet & Liquidity

Current assets around $28-29B vs. current liabilities near $19-22B, implying a healthy liquidity cushion (latest current ratio ~1.3–1.4).
Noncurrent liabilities about $13-14B against equity of roughly $31-33B, with total assets near $63-69B, indicating solid balance-sheet resilience and solvency dynamics.

⚠️ Key Drivers & Risks

Drivers: AI & Data/Cloud transformation demand; scalable global services with cross-sell opportunities.
Risks: cyclicality in IT spend, valuation sensitivity to growth expectations, competitive intensity.

Similar Companies

ABBV Score: 59 BSX Score: 81 ELV Score: 77 ISRG Score: 85 JNJ Score: 79 MDT Score: 67 TMO Score: 75 TSLA Score: 62

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"